DDInter56 DDInter1729
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticlopidine
Ticlopidine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticlopidine
Ticlopidine {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulindac
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Alteplase {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Regorafenib {u} (Compound) causes {v} (Side Effect) Protein urine present
Protein urine present {u} (Side Effect) is caused by {v} (Compound) Sulindac
Alteplase {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Apixaban {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Alteplase {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulindac (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Alteplase may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib (Compound) causes Protein urine present (Side Effect) and Protein urine present (Side Effect) is caused by Sulindac (Compound)
Alteplase may lead to a major life threatening interaction when taken with Apixaban and Apixaban (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Alteplase may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)